❯ Pathos AI closes a $237 million round led by BMS and expands drug-development collaborations

The financing has closedOn October 23, Pathos AI announced a $237 million Series E at an approximately $3 billion post-money valuation, led by Bristol Myers Squibb (BMS). Its May 2025 Series D raised $365 million at an approximately $1.6 billion post-money valuation.

An AI platform alongside clinical assetsPathos Foundry combines clinical, genomic and other program information to support asset selection, patient stratification and trial decisions. The company also advances its own clinical pipeline. Proceeds will expand the platform and support development, including work toward registrational studies for the licensed bispecific antibody-drug conjugate JSKN016.

Pharma partnerships create specific applicationsPathos also announced multiyear collaborations with BMS and Tempus for Alzheimer’s and other neurological conditions. Pathos will license a Tempus-built dataset under a five-year, $55 million agreement; BMS receives platform access and defined neuroscience collaboration rights. These arrangements connect pharmaceutical expertise, patient data and the AI platform to concrete programs. Clinical efficacy and development efficiency still require separate evidence.

▮ SIGNALDrug-development AI is advancing through platforms, clinical data and pharma partnerships, with capital tied to defined research and clinical milestones.